Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Intraventricularly injected Olig2-NSCs attenuate established relapsing-remitting EAE in mice.
Preventive healthcare use among males with multiple sclerosis.
Optic nerve magnetisation transfer ratio after acute optic neuritis predicts axonal and visual outcomes.
Epidural analgesia and cesarean delivery in multiple sclerosis post-partum relapses: the Italian cohort study.
Prevention and diminished expression of experimental autoimmune encephalomyelitis by low dose naltrexone (LDN) or opioid growth factor (OGF) for an extended period: Therapeutic implications for multiple sclerosis.
Primary progressive multiple sclerosis: part of the MS disease spectrum or separate disease entity?
Evaluation of the immunosuppressive effects of cyclophosphamide in patients with multiple sclerosis.
[Lyme disease in patients with multiple sclerosis: clinical, diagnostic and therapeutic features.]
White matter volume is decreased in the brain of patients with neuromyelitis optica.
Personalized Medicine in Neurodegenerative Diseases: How Far Away?
Compositional Changes of B and T Cell Subtypes during Fingolimod Treatment in Multiple Sclerosis Patients: A 12-Month Follow-Up Study.
Natalizumab in relapsing-remitting multiple sclerosis.
Regulated microRNAs in the CSF of patients with multiple sclerosis: A case-control study.
Neuromyelitis optica: clinical manifestations and neuroimaging features.
Cyclophosphamide therapy in pediatric multiple sclerosis.
Multiple sclerosis.
Potential Role of Glucagon-Like Peptide-1 (GLP-1) in Neuroprotection.
[Side-effects of glucocorticosteroids in multiple sclerosis: a case report of a patient with global amnesia.]
The refinement of genetic predictors of multiple sclerosis.
Epstein-Barr Virus Specific Antibody Response in Multiple Sclerosis Patients during 21 Months of Natalizumab Treatment.
Early intervention with gene-modified mesenchymal stem cells overexpressing interleukin-4 enhances anti-inflammatory responses and functional recovery in experimental autoimmune demyelination.
Long-term efficacy, tolerability and retention rate of azathioprine in 103 aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder patients: a multicentre retrospective observational study from the UK.
Fine-tuning the central nervous system: microglial modelling of cells and synapses.
Redox regulation of NF-κB p50 and M1 polarization in microglia.
PML-IRIS during Fingolimod Diagnosed after Natalizumab Discontinuation.
Pages
« first
‹ previous
…
198
199
200
201
202
203
204
205
206
…
next ›
last »